Trends in presentation of bone and soft tissue sarcomas over 25 years little evidence of earlier diagnosis

Similar documents
Update on Sarcomas of the Head and Neck. Kevin Harrington

Clinical Study Primary Malignant Tumours of Bone Following Previous Malignancy

What s new in bone and soft tissue sarcoma Treatment and Guidelines 2012? Rob Grimer

The Scandinavian Sarcoma Group annual report on extremity and trunk wall soft tissue and bone sarcomas

Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk

Pathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON

West Midlands Sarcoma Advisory Group

Klinisch belang van chromosomale translocatie detectie in sarcomen

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2

Introduction to Musculoskeletal Tumors. James C. Wittig, MD Orthopedic Oncologist Sarcoma Surgeon

Soluble CD155 As A Biomarker For Malignant Bone And Soft Tissue Tumors

I sarcomi dei tessuti molli

West Midlands Sarcoma Advisory Group

An epidemiological survey of tumour or tumour like conditions in the scapula and periscapular region

New Biological and Immunological Therapies for Cancer

Research Article Primary Leiomyosarcoma of Bone: Analysis of Prognosis

Contents Part I Introduction 1 General Description 2 Natural History: Importance of Size, Site, Histopathology

FALCONS DISTRICT FOOTBALL CLUBS DRIVING SARCOMA AWARENESS & RAISING FUNDS FOR RESEARCH

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

The other bone sarcomas

Incision Care Tutorial

Bone Sarcoma Incidence and Survival. Tumours Diagnosed Between 1985 and Report Number R12/05

Soft Tissue Sarcomas: Questions and Answers

Scandinavian Sarcoma Group. Ass. Prof. Otte Brosjö,, Karolinska Hospital, Stockholm

Scandinavian Sarcoma Group and Oncologic Center, Lund, Sweden. Centralized Registration of Sarcoma Patients in Scandinavia SSG VII:4

Guidelines for the Management of Suspected Sarcoma in Primary Care

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

The Completeness of Soft Tissue Sarcoma Data in the National Cancer Data Repository

Épidémiologie des sarcomes en Belgique

Should soft tissue sarcomas be treated at a specialist centre?

Grading of Bone Tumors

Diagnosis and management of retroperitoneal sarcoma

Shared Care & Survival CTYA SSCRG (Childhood Cancer Research Group)

Managing adult soft tissue sarcomas and gastrointestinal stromal tumours

أملس عضلي غرن = Leiomyosarcoma. Leiomyosarcoma 1 / 5

Ultrasound-guided Percutaneous Trucut Needle Biopsy for Musculoskeletal Tumours

Molecular Diagnosis of Soft Tissue Tumors: Avoid Pitfalls

Q&A. Fabulous Prizes. Collecting Cancer Data: Bone and Soft Tissue 1/10/113. NAACCR Webinar Series

PROBLEMS OF PROGNOSTICATION IN SOFT TISSUE TUMOURS. Christopher D.M. Fletcher Brigham and Women s Hospital and Harvard Medical School Boston, MA

Soluble N-cadherin as a Biomarker for Malignant Bone and Soft Tissue Tumors

Spindle Cell Lesions Of The Breast. Emad Rakha Professor of Breast Pathology and Consultant Pathologist

Pathology Mystery and Surprise

Ultrasound screening of soft tissue masses in the trunk and extremity - a BSG guide for ultrasonographers and primary care

SKELETAL METASTASES FROM SOFT-TISSUE SARCOMAS

Best of ASCO 2014 Sarcoma

International Collaborations on Sarcomas. Alessandro Gronchi

Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers

Rare Cancers. Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Sarcoma Patient Symposium October 15, 2017

Guidelines for the management of soft tissue sarcomas. The British Sarcoma Group Authors:

LAC + USC.

Research Article Immediate versus Delayed Sarcoma Reconstruction: Impact on Outcomes

Annual Report Greater Manchester and Oswestry Sarcoma Service (GMOSS) Specialist Sarcoma MDT. Host Trust Central Manchester Foundation Trust

West Midlands Sarcoma Advisory Group. Guideline for the Clinical Management of Soft Tissue Sarcomas Occurring in Adults

Conceptual Evolution of Soft Tissue Tumors Classification

5/10. Pathology Soft tissue tumors. Farah Bhani. Mohammed Alorjani

Kicking goals for Sarcoma awareness and raising funds for Sarcoma research

Update On Lipomatous Tumors: Old Standbys and New Concepts

Research Article Synovial Chondrosarcoma Arising in Synovial Chondromatosis

Alarm symptoms of soft-tissue and bone sarcoma in patients referred to a specialist center

Author's response to reviews

CONSULTATION DURING SURGERY / NOT A FINAL DIAGNOSIS. FROZEN SECTION DIAGNOSIS: - A. High grade sarcoma. Wait for paraffin sections results.

La chemioterapia neoadiuvante nei sarcomi: novità e attuali indicazioni Lorenzo D Ambrosio, MD PhD Divisione di Oncologia Medica Istituto di Candiolo

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper

Review of the AP Part II Practical Examination. Dr David Clift Co Chief Examiner

SARCOMAS INCIDENCE PREVALENCE SURVIVAL 1 YEARS AFTER DIAGNOSIS OF SARCOMAS ARE RARE ESTIMATED NEW CASES ITALY, 2015

Clinical Study A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas

UK Musculoskeletal Oncology: Something for All Ages. Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky

Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas

Cancer in adolescents and Young Adults

19 th Working Committee Meeting of the Scandinavian Sarcoma Group Malmö

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction

History A 89 year old gentleman presenting with a scalp/forehead nodule. Patient had squamous cell carcinoma 18 m at same site, excised. Outside diagn

Distribution and evaluation of primary bone and soft tissue tumors admitted from Malatya province and surrounding provinces

Methoden / Methods inc. ICCC-3 105

10 th Joint MSK/HSS/IOR Course in. Musculoskeletal Tumor Pathology & Clinical Oncology OCTOBER 10-12, 2017 ZUCKERMAN RESEARCH CENTER NEW YORK CITY

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1

A Summary of Childhood Cancer Statistics in Australia,

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Extraskeletal Osteosarcoma: Clinico-pathologic Features and Results of Multimodal Management

The Relevance of Cytologic Atypia in Cutaneous Neural Tumors

How often should I get a mammogram?

Summary... 2 SARCOMA Neoadjuvant chemotherapy in patients with localised high-risk STS... 3

Guidelines Guidelines for the Management of Soft Tissue Sarcomas

Developing New Drugs for Pediatric Patients with Cancer in Japan. Ayumu Arakawa MD National Cancer Center Hospital (NCCH) JAPAN

Results of thoracotomy in osteogenic sarcoma

Case 8 Soft tissue swelling

WHO Classification of Soft Tissue Tumours

Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas

Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients

Research Article A Clinicopathological Analysis of Soft Tissue Sarcoma with Telangiectatic Changes

Slide Seminar Spanish Society of Pathology

We considered whether a positive margin

Retroperitoneal Sarcomas - A pictorial review

Select 74 Cancer claims

Monophasic Synovial Carcinoma of knee joint- A Case Report and Review of Literature

Malignant Peripheral Nerve Sheath Tumor

Dr. Myo Myint Maw Senior Consultant Physician Medical Oncology Unit Yangon General Hospital

Activity Report April 2013 March 2014

Chapter 2 Natural History: Importance of Size, Site, and Histopathology

Transcription:

Trends in presentation of bone and soft tissue sarcomas over 25 years little evidence of earlier diagnosis Royal Orthopaedic Hospital, Birmingham Rob Grimer, Lee Jeys, Gemma Smith, Graham Johnson

Are we getting better? Sarcomas are frequently not recognised by: Patients GPs Hospital doctors As a result there are often long delays before they are diagnosed

What do we know already Sarcomas are diagnosed late Only 16.5% are diagnosed through the 2 week wait clinic Of GP referrals only 13% are malignant Delays in diagnosis occur at every stage in the patient pathway Numerous Cancer Plans and early diagnosis initiatives have been introduced Have they worked??

How can we tell if we are getting better? Duration of symptoms Size at time of diagnosis Appropriate referral By stopping people presenting like this? Had been seeing GP for 1 year with ulcer In fact high grade STS

Method Analysis of prospectively kept database Size at presentation Duration of symptoms ( how long have you had any symptoms related to this...?) Proportion of whoops procedures Analysed over a 25 year period

The patients: 4934 patients 2568 bone sarcomas 1240 osteosarcomas 539 chondrosarcomas 459 Ewing s sarcomas 276 spindle cell sarcomas 54 others 2366 STS

Bone Sarcomas Mean size = 10.7 cm Osteosarcoma 10.7cm Chondrosarcoma 11.3cm Ewing s sarcoma 9.9cm Spindle cell sarcoma 10.4cm

29 yr old felt he was sitting on a knobbly seat while on way on honeymoon to Maldives worried? He was sitting on a 15cm chondrosarcoma!

Count Size distribution - Osteosarcoma 160 140 120 100 80 Mean size 10.5cm 10.9cm, 10.1cm 60 40 20 0 0 5 10 15 20 25 30 35 40 Size in cm

1986.000 1987.000 1988.000 1989.000 1990.000 1991.000 1992.000 1993.000 1994.000 1995.000 1996.000 1997.000 1998.000 1999.000 2000.000 2001.000 2002.000 2003.000 2004.000 2005.000 2006.000 2007.000 2008.000 2009.000 SizeA Are we getting better OS size? 45 40 35 30 25 20 15 10 5 0 Size at diagnosis - unchanged over 25 years 10.5cm

STS Mean size = 9.9 cm (range 0.3 to 47cm) Liposarcoma 13.3cm MPNST 10.5cm MFH 10.3cm Leiomyosarcoma 7.7cm Synovial sarcoma 6.9cm Epithelioid sarcoma 3cm

Mean size (cms) Mean size of Sarcomas over 25 yrs 30 25 20 Soft Tissue Sarcoma 15 95% CI Bone sarcoma 95% CI 10 5 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 Bone sarcomas - no change, with time STS slightly improved from 10.3cm in 1990s to 9.6cm since 2000

Weeks Duration of symptoms Bone sarcomas median16 weeks STS median 26 weeks 200 175 150 125 100 75 50 25 Bone STS Bone sarcoma STS 0 DuratSymp

Median duration (weeks) Median duration of symptoms 70 60 50 40 30 Soft Tissue Sarcoma IQR Bone sarcoma IQR 20 10 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 Claimed duration of symptoms is INCREASING for bone sarcomas Increased from 16 to 20 weeks since 2000 STS symptom duration unchanged (26 weeks)

Duration of symptoms by diagnosis Bone sarcomas STS Osteosarcoma 12 weeks Liposarcoma 28 weeks Chondrosarcoma 52 weeks Leiomyosarcoma 26 weeks Ewings 20 weeks MFH 20 weeks Spindle cell sarcoma 20 weeks Synovial sarcoma 52 weeks Chordoma 104 weeks MPNST 26 weeks

Other factors sex Symptom duration no difference between males and females for bone or STS Size Women present earlier STS 10.1cm vs 9.5cm (p=0.04) Bone - 10.5cm vs 9.8cm (p=0.008)

Does age affect it? Age group < 10 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ Size (cms) Soft Tissue Sarcomas 4.2 7.4 8.2 8.9 10.0 10.5 10.3 10.3 11.1 Bone Sarcomas (cms) 9.8 10.5 10.1 10.1 9.6 11.6 10.6 11.9 11.6 Symptom duration (weeks - median) Soft Tissue Sarcomas 8 16 26 26 26 26 26 20 26 Bone Sarcomas 7 12 20 26 36 36 32 28 26 Older patients have bigger tumours and somewhat longer duration of Sx

Does site matter? STS Superficial tumours = 6cm Deep tumours = 11.2cm

% prev.inadvertent excision Mean size (cm) Whoops! 25% of patients had had a previous inadvertent excision, mean size 5.8cm Slight decrease in incidence with time, but size unchanged 55 50 45 40 35 30 25 20 15 10 5 0-5 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 previous inadvertent excision Size 95% CI

More whoops 55% of all superficial STS had a previous whoops, (338 of 615) Mean size was 5cm compared to 7.0cm for those treated primarily 15% of all deep STS had a previous whoops (262 of 1751) Mean size was 7cm compared to 12cm for those treated primarily

Why are they missed?? Painful shoulder 4 months 35 yr old 6 weeks later Low level of awareness?

Bigger is NOT better! All these countries have better Why? outcomes (STS) Scandinavia 7cm Italy Australia UK 6cm 7cm 10cm Aren t we aren t bothered about lumps and bumps? Are our doctors not worried? We need a new strategy... (all ideas welcome!)

Does earlier diagnosis = better outcomes? Patients are happier with less delay Easier to treat Less risk of metastases at diagnosis 30 25 20 15 10 Bone STS 5 0 <5cm 6 to 10cm 11 to 15cm 16-20 cm >20cm

Cum. Survival and better survival... All sarcomas survival by size 1.8.6.4.2 0 <5cm Cum. Survival (under 5 Event Times (under 5) <10cm Cum. Survival (five to Event Times (five to ten) <15cm Cum. Survival (ekeven Event Times (ekeven to Cum. Survival (sixteen <20 cm Event Times (sixteen to Cum. Survival (over 20 >20cm Event Times (over 20) 0 20 40 60 80 100 Time in months

Conclusion Bone and soft tissue sarcomas are diagnosed late We re not getting better None of the UK guidance (2000 and 2005) on early diagnosis or the 2006 Improving Outcomes Guidance or the introduction of 2 week waits has made any obvious difference.

Prof Sir Mike Richards.. We know the main reason our survival rates lag behind other countries is because too many people are diagnosed late. This is why our Strategy focuses on earlier diagnosis which we will achieve through raising the public s awareness of the signs and symptoms of cancer and also providing better access to diagnostic tests. (Improving outcomes a strategy for cancer, 2011)... but will it happen for sarcomas????